The purpose of this investigation was to conduct a prospective trial to assess the effectiveness of a 4% sclerosing alcohol injection in a small group of patients with intermetatarsal neuromas who had failed previous conservative therapies including corticosteroid injections. Six patients with 8 
intermetatarsal, injection
Intermetatarsal neuroma, or Morton's neuroma is one of the most frequently encountered pathologies in the foot and ankle practice. Patients often complain of intense pain in the forefoot with burning, tingling or numbness that radiates to the toes. Diagnosis of intermetatarsal neuroma is made principally by a thorough clinical examination, but magnetic resonance imaging and ultrasound have shown to be helpful (1, 2). Treatment for Morton's neuroma first focuses on conservative therapies such as a change in shoe gear, padding, orthoses, physical therapy, and corticosteroid injections. The reported success rate for conservative treatment has ranged from 85% to as low as 30% (3-5). Corticosteroid injections are effective but have potential complications, including hyperpigmentation, skin atrophy, telangiectasias, and painful plantar fat pad atrophy (6, 7).
Typically, in patients with neuroma pain recalcitrant to conservative measures, the next step is surgery. Some authors suggest surgical excision as the primary treatment, but most practitioners wait until conservative means have been exhausted (4, 8) . Many studies of surgical treatments have reported a 70%-85% clinical improvement rate (8-12). However, as with any surgery, complications such as deep wound infection, wound dehiscence, persistent erythema, hypertrophic scarring, recurrence, and a need for further surgery are possible (8-1 1, 14) . Another disadvantage of surgery is the potential time lost from activities and work. Patients can return to their normal activities 2 months postoperatively, but may experience persistent swelling and pain for up to 6 months (8, 11).
Recently, chemical neurolysis using a 4% sclerosing alcohol injection has been reported as a possible alternative treatment for intermetatarsal neuromas (5, 13). One study yielded an 89% success rate using the 4% sclerosing alcohol injections in patients with previously untreated neuromas (5). The purpose of this study was to prospectively measure the success of the sclerosing injection for recalcitrant intermetatarsal neuromas in a small pilot group of patients who had failed previous conservative therapies including corticosteroid injection.
Materials and Methods
This pilot study consisted of 8 subjects from 3 clinic populations with 14 intermetatarsal neuromas. Patients were VOLUME 44, NUMBER 4, JULYIAUGUST 2005 Subjective:
Type of symptoms:
Duration of Symptoms: 0-3 mos, 4-6 mos, 7-9 mos, 10-12 mos, 1-2 yrs, 2-3 yrs, > 3 yr. often treated by the resident staff with the supervision of 2 attending physicians (A.J.B., R.J.V.). Only adult subjects were used. All subjects completed an appropriate consent specifying that a minimum of 3 and a maximum of 9 weekly injections might be needed. Subjects for inclusion were those with a clinical diagnosis of intermetatarsal neuroma in any intermetatarsal space who had undergone previous conservative treatment. Exclusion criteria included patients with metatarsal stress fracture, tarsal tunnel syndrome, lesser metatarsophalangeal joint instability, or new onset neuroma determined by clinical exam. All enrolled subjects completed a pretreatment survey consisting of both subjective and objective data (Fig 1) . Subjective data included demographic information, the duration and type of symptoms, previous treatments that were either self-or professionally administered, and a pain rating using a visual analog scale (VAS). Objective data included an indication of the intermetatarsal space involved and the point of maximal tenderness (PMT) measured on the involved webspace. A positive or negative Mulder's click found on palpation of the webspace and pain upon lateral compression of the forefoot during palpation of the webspace was also documented. A similar survey was completed at each weekly visit prior to the next injection. The
